Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria
Open Access
- 31 October 2019
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 16 (3) , 673-683
Abstract
The development of more effective vaccines against Mycobacterium tuberculosis has become a world priority. Previously, we have shown that a recombinant BCG expressing the LTAK63 adjuvant (rBCG-LTAK63) displayed higher protection than BCG against tuberculosis challenge in mice. In order to elucidate the immune effector mechanisms induced by rBCG-LTAK63, we evaluated the immune response before and after challenge. The potential to induce an innate immune response was investigated by intraperitoneal immunization with BCG or rBCG-LTAK63: both displayed increased cellular infiltration in the peritoneum with high numbers of neutrophils at 24 h and macrophages at 7 d. The rBCG-LTAK63-immunized mice displayed increased production of Nitric Oxide at 24 h and Hydrogen Peroxide at 7 d. The number of lymphocytes was higher in the rBCG-LTAK63 group when compared to BCG. Immunophenotyping of lymphocytes showed that rBCG-LTAK63 immunization increased CD4+ and CD8+ T cells. An increased long-term Th1/Th17 cytokine profile was observed 90 d after subcutaneous immunization with rBCG-LTAK63. The evaluation of immune responses at 15 d after challenge showed that rBCG-LTAK63-immunized mice displayed increased TNF-α-secreting CD4+ T cells and multifunctional IL-2+ TNF-α+ CD4+ T cells as compared to BCG-immunized mice. Our results suggest that immunization with rBCG-LTAK63 induces enhanced innate and long-term immune responses as compared to BCG. These results can be correlated with the superior protection induced against TB.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2017/24832-6)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/01271-0)
This publication has 52 references indexed in Scilit:
- Mice genetically inactivated in interleukin‐17A receptor are defective in long‐term control of Mycobacterium tuberculosis infectionImmunology, 2013
- Prominent role for T cell-derived Tumour Necrosis Factor for sustained control of Mycobacterium tuberculosis infectionScientific Reports, 2013
- Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary TuberculosisPulmonary Medicine, 2012
- Tuberculosis vaccines: beyond bacille Calmette–GuérinPhilosophical Transactions of the Royal Society B: Biological Sciences, 2011
- Recombinant BCG ΔureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine ResponsesThe Journal of Infectious Diseases, 2011
- Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX proteinVaccine, 2010
- Cell-Mediated Immune Responses in TuberculosisAnnual Review of Immunology, 2009
- Enhanced and Enduring Protection against Tuberculosis by Recombinant BCG-Ag85C and Its Association with Modulation of Cytokine Profile in LungPLOS ONE, 2008
- Methods to detect nitric oxide and its metabolites in biological samplesFree Radical Biology and Medicine, 2007
- Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosisNature Medicine, 2003